Molnupiravir Anti Viral Drug May Work Against Omicron & Other Variants

Molnupiravir Anti Viral Drug: Ever since the Omicron variant of coronavirus started devastating people’s lives globally, researchers continued to work hard to make such an antiviral drug that could work not only against the omicron variant but also other coronavirus variants. And now, it looks like they have somewhat achieved their task.

As per a new study conducted in this regard, Molnupiravir is going to be an anti viral drug expected to work against many coronavirus variants including omicron. Now, if the drug will be actually effective will be evident in the time to come.

The study also suggests that Molnupiravir will be more beneficial as compared to monoclonal antibodies.

As we mentioned above, there is no clinical proof or study available to support that it will actively work against all new and old variants of coronavirus.


Molnupiravir Anti Viral Drug May Work Against Omicron & Other Variants

The above study was conducted and published in the journal, Diabetes & Metabolic Syndrome: Clinical Research & Reviews. It said, “subgroup analysis found molnupiravir was effective irrespective of strain although no data is available for its effect on Omicron in particular” it said.

It further added, “Unlike monoclonal antibodies, the mechanism of action of molnupiravir is independent of mutations in the spike protein, and thus it is expected to work against Omicron, theoretically.

“Indeed, in vitro study of VeroE6-GFP cells does indicate that molnupiravir retain their activity against the VOCs of Alpha, Beta, Gamma, Delta, and Omicron.”

As per an update the above findings were jointly analyzed by doctors from Diabetes Institute and Fortis hospital.

This is what Dr Anoop Misra, Executive Chairman and Director, Diabetes and Endocrinology, Fortis C-DOC, told IANS, “In general, there is no doubt it is effective against Omicron, but yes it has not been tested,”

He further added, “Molnupiravir, on the other hand, can be used in out-patient settings through oral route with a lower cost.” He further added, “these findings are very important in the context of India”.

The study conducted in this regard states that a 5 day course of Molnupiravir anti viral drug is expected to reduce causalities and also prove safe and effective. At the same time the drug should be available at lower costs. Mishra said the drug doesn’t look like having some adverse effects.

Mishra warned by stating, “inappropriate and injudicious use in too many individuals without assessing risk”. he said.

The study conducted recently stated that adults over the age of 18 years can take molnupiravir. The same applies to non pregnant women.

This is what Mishra stated in a statement released, “From the available evidence, Molnupiravir appears to be a reasonably useful drug in reducing deaths and hospitalization in adult patients with Covid-19 having high risk, with a relatively lower cost,” he said.

It “could be a useful drug in non-pregnant unvaccinated adults with Covid-19 who are at increased risk of severity including hospitalization,” he added.

Molnupiravir is developed by the the US Food and Drug Administration against Covid-19.

Please know hat Molnupiravir is an antiviral drug prepared for new covid variants of coronavirus. This drug will be manufactured by over 13 companies in India.

Also Read: Yellow Tongue Causes, Symptoms & Treatment



Related Articles

Stay Connected


Latest Articles